Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Aspira and Oxford University Test Endometriosis Diagnostic

Aspira and Oxford University Test Endometriosis Diagnostic

11th September 2023

In order to gather serum samples for the purpose of testing and confirming the effectiveness of its endometriosis diagnostic, Aspira Women’s Health has inked a contract of material transfer with the University of Oxford.

By the close of 2023, Texas-based Aspira hopes to introduce its EndoCheck blood test for endometriosis to market.

The examination is intended to be used in conjunction with other nonsurgical methods to help with endometriosis detection. According to Aspira, it should provide accuracy and precision levels on par with commonly employed invasive techniques like surgery and imaging.

Chief Executive Officer of Aspira, Nicole Sandford, explained that they “are excited to enter into this agreement with the University of Oxford. With their samples, we will be able to drive our EndoCheck validation process forward and bring this much needed test to market.”

Joint Director of the Oxford Endometriosis Care Centre, Christian Becker, explained that “an important step towards improving outcomes for women with endometriosis is faster, more reliable diagnosis.” He continued: “we are excited to support Aspira Women’s Health in developing a much-needed test for the identification of this debilitating disease.”

Economic parameters and other details of the partnership weren’t made public.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.